Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Debruyne

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Journal of Clinical Medicine|October 16, 2024
Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1Herjan J T Coelingh Bennink, Erik P M Roos, R Jeroen A van Moorselaar, et al.
Endocrine Connections|October 25, 2022
Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative reviewHerjan J T Coelingh Bennink, Jan Krijgh, Jan F M Egberts, et al.
BJU International|July 14, 2016
Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in MenFrans M J Debruyne, Hermann M Behre, Claus G Roehrborn, et al.
European Urology Open Science|November 10, 2022
Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi StudyYvette Zimmerman, Mark Frydenberg, Hendrik van Poppel, et al.
European Urology Open Science|August 2, 2021
Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)Herjan J T Coelingh Bennink, Jeroen A van Moorselaar, E David Crawford, et al.
The Lancet. Oncology|December 24, 2016
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trialAbdel-Rahmène Azzouzi, Sébastien Vincendeau, Eric Barret, et al.
The Journal of Sexual Medicine|August 8, 2017
Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME)Raymond C Rosen, Frederick Wu, Hermann M Behre, et al.
International Journal of Impotence Research|June 12, 2002
A shared care approach to the management of erectile dysfunction in the communityG Wagner, H Claes, P Costa, et al.
Thescientificworldjournal|April 2, 2014
Cochlear implant programming: a global survey on the state of the artBart Vaerenberg, Cas Smits, Geert De Ceulaer, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Journal of Clinical Medicine|October 16, 2024
Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1Herjan J T Coelingh Bennink, Erik P M Roos, R Jeroen A van Moorselaar, et al.
Endocrine Connections|October 25, 2022
Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative reviewHerjan J T Coelingh Bennink, Jan Krijgh, Jan F M Egberts, et al.
BJU International|July 14, 2016
Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in MenFrans M J Debruyne, Hermann M Behre, Claus G Roehrborn, et al.
European Urology Open Science|November 10, 2022
Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi StudyYvette Zimmerman, Mark Frydenberg, Hendrik van Poppel, et al.
European Urology Open Science|August 2, 2021
Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)Herjan J T Coelingh Bennink, Jeroen A van Moorselaar, E David Crawford, et al.
The Lancet. Oncology|December 24, 2016
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trialAbdel-Rahmène Azzouzi, Sébastien Vincendeau, Eric Barret, et al.
The Journal of Sexual Medicine|August 8, 2017
Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME)Raymond C Rosen, Frederick Wu, Hermann M Behre, et al.
International Journal of Impotence Research|June 12, 2002
A shared care approach to the management of erectile dysfunction in the communityG Wagner, H Claes, P Costa, et al.
Thescientificworldjournal|April 2, 2014
Cochlear implant programming: a global survey on the state of the artBart Vaerenberg, Cas Smits, Geert De Ceulaer, et al.
Pageof 8